Results 31 to 40 of about 159,686 (49)

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

The Lancet, 2012
B. Voight, G. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalić, M. Jensen, G. Hindy, H. Hólm, E. Ding, T. Johnson, H. Schunkert, N. Samani, R. Clarke, J. Hopewell, John F. Thompson, Mingyao Li, G. Thorleifsson, C. Newton‐Cheh, K. Musunuru, J. Pirruccello, D. Saleheen, Li Chen, A. Stewart, A. Schillert, U. Thorsteinsdóttir, G. Thorgeirsson, Sonia S Anand, J. Engert, T. Morgan, J. Spertus, M. Stoll, K. Berger, N. Martinelli, D. Girelli, P. McKeown, C. Patterson, S. Epstein, J. Devaney, M. Burnett, V. Mooser, S. Ripatti, I. Surakka, M. Nieminen, J. Sinisalo, M. Lokki, M. Perola, A. Havulinna, U. de Faire, B. Gigante, E. Ingelsson, T. Zeller, P. Wild, P. D. de Bakker, O. Klungel, A. H. Maitland‐van der Zee, B. Peters, A. de Boer, D. Grobbee, P. Kamphuisen, V. Deneer, Clara C Elbers, N. Onland-Moret, M. Hofker, C. Wijmenga, W. Verschuren, J. Boer, Y. T. van der Schouw, A. Rasheed, P. Frossard, S. Demissie, C. Willer, R. Do, J. Ordovás, G. Abecasis, M. Boehnke, K. Mohlke, M. Daly, C. Guiducci, N. Burtt, Aarti Surti, Elena Gonzalez, S. Purcell, S. Gabriel, J. Marrugat, J. Peden, J. Erdmann, P. Diemert, C. Willenborg, I. König, M. Fischer, C. Hengstenberg, A. Ziegler, I. Buysschaert, D. Lambrechts, F. Van de Werf, K. Fox, N. E. El Mokhtari, Diana Rubin, J. Schrezenmeir, S. Schreiber, Arne S Schäfer, J. Danesh, S. Blankenberg, R. Roberts, R. McPherson, H. Watkins, A. Hall, K. Overvad, E. Rimm, E. Boerwinkle, A. Tybjaerg-hansen, L. Cupples, M. Reilly, O. Melander, P. Mannucci, D. Ardissino, D. Siscovick, R. Elosúa, K. Stefánsson, C. O’Donnell, V. Salomaa, D. Rader, L. Peltonen, S. Schwartz, D. Altshuler, S. Kathiresan   +125 more
semanticscholar   +1 more source

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

, 2012
P. P. Toth
semanticscholar   +1 more source

Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

Science, 2016
P. Zanoni, Sumeet A. Khetarpal, Daniel B Larach, William Hancock-Cerutti, John S. Millar, M. Cuchel, S. Derohannessian, A. Kontush, P. Surendran, D. Saleheen, S. Trompet, J. Jukema, A. D. de Craen, P. Deloukas, N. Sattar, I. Ford, C. Packard, Abdullah al Shafi Majumder, Dewan S. Alam, E. di Angelantonio, G. Abecasis, Rajiv Chowdhury, J. Erdmann, B. Nordestgaard, S. Nielsen, A. Tybjærg‐Hansen, Ruth Frikke Schmidt, K. Kuulasmaa, Dajiang J. Liu, M. Perola, S. Blankenberg, V. Salomaa, S. Männistö, P. Amouyel, D. Arveiler, J. Ferrières, M. Müller-Nurasyid, M. Ferrario, F. Kee, C. Willer, N. Samani, H. Schunkert, A. Butterworth, J. Howson, G. Peloso, N. Stitziel, J. Danesh, S. Kathiresan, Daniel J. Rader   +48 more
semanticscholar   +1 more source

U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies

European Heart Journal, 2018
C. M. Madsen, A. Varbo, A. Tybjærg‐Hansen, R. Frikke-Schmidt, B. Nordestgaard   +4 more
semanticscholar   +1 more source

HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation

Science Signaling, 2015
S. Galvani, M. Sanson, V. Blaho, S. Swendeman, Hideru Obinata, H. Conger, B. Dahlbäck, M. Kono, R. Proia, Jonathan D. Smith, T. Hla   +10 more
semanticscholar   +1 more source

Time to ditch HDL-C as a measure of HDL function?

Current Opinion in Lipidology, 2017
G. Ronsein, J. Heinecke
semanticscholar   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Monocyte‐to‐HDL‐cholesterol ratio as a prognostic marker in cardiovascular diseases

Journal of Cellular Physiology, 2018
Inflammation and lipid accumulation are two basic hallmarks of atherosclerosis as a chronic disease. Inflammation not only is a local response but can also be considered as a systemic process followed by an elevation of inflammatory mediators.
S. Ganjali, A. Gotto, M. Ruscica, S. Atkin, A. Butler, M. Banach, A. Sahebkar   +6 more
semanticscholar   +1 more source

High-density Lipoprotein (HDL) Dysfunction and the Future of HDL.

Current Vascular Pharmacology, 2017
Although High Density Lipoprotein Cholesterol (HDL-C) levels are inversely proportional to cardiovascular risk in many studies, recent pharmacological interventional studies with HDL-C raising strategies did not show a benefit in terms of vascular events.
S. Ertek
semanticscholar   +1 more source

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology

Nature Reviews Cardiology, 2018
R. Rosenson, Bryan H. Brewer, P. Barter, J. Björkegren, John M. Chapman, D. Gaudet, D. S. Kim, E. Niesor, K. Rye, F. Sacks, J. Tardif, R. Hegele   +11 more
semanticscholar   +1 more source

Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease

Molecular and Cellular Biochemistry, 2018
R. Srivastava
semanticscholar   +1 more source